Nothing Special   »   [go: up one dir, main page]

WO2011035018A3 - Suicide ready cells - Google Patents

Suicide ready cells Download PDF

Info

Publication number
WO2011035018A3
WO2011035018A3 PCT/US2010/049112 US2010049112W WO2011035018A3 WO 2011035018 A3 WO2011035018 A3 WO 2011035018A3 US 2010049112 W US2010049112 W US 2010049112W WO 2011035018 A3 WO2011035018 A3 WO 2011035018A3
Authority
WO
WIPO (PCT)
Prior art keywords
suicide
cell
present
based compositions
ready cells
Prior art date
Application number
PCT/US2010/049112
Other languages
French (fr)
Other versions
WO2011035018A2 (en
Inventor
John D. Mendlein
Paul Grayson
Original Assignee
Fate Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics, Inc. filed Critical Fate Therapeutics, Inc.
Publication of WO2011035018A2 publication Critical patent/WO2011035018A2/en
Publication of WO2011035018A3 publication Critical patent/WO2011035018A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention includes methods of providing treatment to individuals in need of cell, tissue, and/or organ repair, regeneration, restoration, and/or replacement by administering cell-based compositions. The cell-based compositions of the present invention have features that increase both the safety and therapeutic efficacy of regenerative therapy. The present invention also includes implants that can be used to provide regenerative therapy.
PCT/US2010/049112 2009-09-18 2010-09-16 Suicide ready cells WO2011035018A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24392109P 2009-09-18 2009-09-18
US61/243,921 2009-09-18

Publications (2)

Publication Number Publication Date
WO2011035018A2 WO2011035018A2 (en) 2011-03-24
WO2011035018A3 true WO2011035018A3 (en) 2011-07-21

Family

ID=43759270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/049112 WO2011035018A2 (en) 2009-09-18 2010-09-16 Suicide ready cells

Country Status (1)

Country Link
WO (1) WO2011035018A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
EP3831840A1 (en) * 2013-03-15 2021-06-09 Celgene Corporation Modified t lymphocytes
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
JP6718444B2 (en) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
KR101752697B1 (en) * 2015-04-17 2017-07-03 (주)나디안바이오 Composition for Treating or Preventing Pancreatitis Comprising Naphthoquinone-based Compounds
CN105963683A (en) * 2016-04-12 2016-09-28 青岛市中心医院 Application of Sirt1 in repairing corneal nerve injury
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20230104317A1 (en) * 2020-01-31 2023-04-06 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods to Identify Genetic Silencers and Applications Thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114113A (en) * 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
US20070031391A1 (en) * 1998-08-14 2007-02-08 Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US20070071675A1 (en) * 2005-08-19 2007-03-29 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US20080038296A1 (en) * 2006-06-23 2008-02-14 Engeneic Gene Therapy Pty Limited Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114113A (en) * 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
US20070031391A1 (en) * 1998-08-14 2007-02-08 Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
US20070071675A1 (en) * 2005-08-19 2007-03-29 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US20080038296A1 (en) * 2006-06-23 2008-02-14 Engeneic Gene Therapy Pty Limited Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Also Published As

Publication number Publication date
WO2011035018A2 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
WO2011035018A3 (en) Suicide ready cells
MX2013013560A (en) Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells.
CY1116344T1 (en) CELLS FROM THE Umbilical Cord Web for Neuropathic Pain and Spasticity Therapy
WO2008021196A3 (en) Methods and compositions for the treatment of medical disorders
MX2012011543A (en) Treatment of sarcoidosis using placental stem cells.
MX2010005642A (en) Preparations, methods and kits useful for treatment of cough.
WO2009134866A3 (en) Cell membrane engineering
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
WO2009046377A3 (en) Compositions and methods of stem cell therapy for autism
MX2012002449A (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency.
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2007149548A3 (en) Treatment of erectile dysfunction by stem cell therapy
MX2009010066A (en) Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer.
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
WO2007127273A3 (en) Methods and compositions for altering cell function
HK1145149A1 (en) Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection
IN2012DN02645A (en)
BRPI0912292A2 (en) compositions and methods for the use of cells in the treatment of cardiac tissue.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EP2608797A4 (en) Bone marrow derived cd271 precursor cells for cardiac repair
WO2009095261A3 (en) Vaccine compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10817823

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10817823

Country of ref document: EP

Kind code of ref document: A2